Alex Ruoff

Top senators on a health committee have agreed on most provisions to reauthorize broad public health programs, but remain apart over including changes to price controls and vouchers for drug companies.

Lawmakers return this week, aiming to make progress on key authorizations and appropriations ahead of August recess and looming deadlines this fall.

Key Democrats remain opposed to President Joe Biden’s choice to lead the nation’s premier federal research agency after she declined to sign an ethics pledge this week.

Generic insulin is more costly and harder to reach than drugmakers have advertised, according to a new report commissioned by Democrats in the Senate.

United Airlines Inc. spent more on federal lobbying in the second quarter of this year than ever before, while the US Chamber of Commerce, Meta Platforms Inc. and Amazon Services Inc. also spent big to influence lawmakers.

The Health Resources and Services Administration would be allowed to award contracts to public and private entities through a competitive process to operate different aspects of the Organ Procurement and Transplantation Network under H.R. 2544.

Lawmakers are ramping up bipartisan efforts to crack down on pharmacy benefit managers (PBM), accusing the industry middlemen of driving up drug costs and putting small and rural pharmacies out of business.

Wetlands and waterways on federal public lands are vulnerable to pollution and development in the wake of the Supreme Court’s May ruling in Sackett v. EPA, natural resources attorneys say.

Lawmakers are debating whether to simply cap how much people pay for insulin or to tackle the root issues that have driven up the cost of medicine. Addressing the problem is critical. More than 37 million Americans have diabetes and more than 7 million need insulin daily. Paying for it is eating up a greater share of their household income than ever before.

The drugmakers suing the US government in multiple courts to block drug price negotiations are doing so for good reason—they’re the ones that stand to lose the most in Medicare’s first-ever plan to control the cost of medicines it spends the most on.